evolocumab
amgen
['fourier']
new from + based on &gt;3,000 participants in fourier pcsk9 mab study with ldl-c &lt;20. two questions: is it helpful?
-&gt; yes, substantial risk reduction down to ldl-c &lt; 10 (!) is it safe?
-&gt; yes, no gradient in risk of adverse events detected #aha22 
Cardiology, human genetics, population biology, and clinical development @VerveTx by way of @MGHMedicine, @broadinstitute, @MGHCVFellows, @BrighamMedRes